Return to Today's science sparks archives

Information Click the tweet icon above each article title to share it on Twitter.

2007-12-28

Fig 4C. Control uninjected Xenopus embryos and embryos injected with the indicated reagents are shown (side view) with the head to the left.

Fig 4C. Control uninjected Xenopus embryos and embryos injected with the indicated reagents are shown (side view) with the head to the left.
  • Joo HY, Zhai L, Yang C, Nie S, Erdjument-Bromage H, Tempst P, Chang C, Wang H

  • Nature. 2007 Oct 25;449(7165):1068-72.

2007-12-26

Fig 6A. α SGT is predicted to interact with a short peptide sequence in the AR hinge that structurally resembles the COOH-terminal EEVD peptides from Hsp70 and Hsp90.

Fig 6A. α SGT is predicted to interact with a short peptide sequence in the AR hinge that structurally resembles the COOH-terminal EEVD peptides from Hsp70 and Hsp90.
  • Buchanan G, Ricciardelli C, Harris JM, Prescott J, Yu ZC, Jia L, Butler LM, Marshall VR, Scher HI, Gerald WL, Coetzee GA, Tilley WD

  • Cancer Res. 2007 Oct 15;67(20):10087-96.

2007-12-21

Fig 1B. The anatomy of the meninges as it surrounds the spinal cord.

Fig 1B. The anatomy of the meninges as it surrounds the spinal cord.
  • O'Meara WP, Borkar SA, Stambuk HE, Lymberis SC

  • Curr Probl Cancer. 2007 Nov-Dec;31(6):372-424.

2007-12-20

Fig 1E. Postoperative posterior view. Note well-healed donor site.

Fig 1E. Postoperative posterior view. Note well-healed donor site.
  • Cordeiro CN, McCarthy CM, Mastorakos DP, Cordeiro PG

  • Ann Plast Surg. 2007 Oct;59(4):451-2.

2007-12-19

Fig 1D. Confocal microscopic immunofluorescent image of hyperplastic islet cells revealed TVA (red) and PDX1 (green) in pancreatic section of a 7-wk-old

Fig 1D. Confocal microscopic immunofluorescent image of hyperplastic islet cells revealed TVA (red) and PDX1 (green) in pancreatic section of a 7-wk-old
  • Du YC, Lewis BC, Hanahan D, Varmus H

  • PLoS Biol. 2007 Oct 16;5(10):2255-69.

2007-12-18

Fig 5. Modified technique for nerve-sparing surgery.

Fig 5. Modified technique for nerve-sparing surgery.
  • James A. Eastham

  • Nat Clin Pract Urol. 2007 Oct;4(10):561-9.

2007-12-17

Fig 1A. Ribbon diagram of the Rad4ñRad23ñDNA complex: TGD, gold; BHD1, magenta; BHD2, cyan; BHD3, red; R4BD, green; and DNA, grey. The two disordered CPD-linked thymidines are indicated schematically, and the two flipped-out thymidines bound to Rad4 are coloured black. Dotted lines indicate disordered regions.

Fig 1A. Ribbon diagram of the Rad4ñRad23ñDNA complex: TGD, gold; BHD1, magenta; BHD2, cyan; BHD3, red; R4BD, green; and DNA, grey. The two disordered CPD-linked thymidines are indicated schematically, and the two flipped-out thymidines bound to Rad4 are coloured black. Dotted lines indicate disordered regions.
  • Min JH, Pavletich NP

  • Nature. 2007 Oct 4;449(7162):570-5.

2007-12-14

Fig 2. Patient with nonñsmall cell lung cancer and increasing metastatic disease with new lung and liver (not shown) lesions.

Fig 2. Patient with nonñsmall cell lung cancer and increasing metastatic disease with new lung and liver (not shown) lesions.
  • Gollub MJ, Hong R, Sarasohn DM, Akhurst T

  • J Nucl Med. 2007 Oct;48(10):1583-91.

2007-12-13

Fig 4B. Coexpression of phospho-RTKs in cells dissociated from primary GBM MSK199.

Fig 4B. Coexpression of phospho-RTKs in cells dissociated from primary GBM MSK199.
  • Stommel JM, Kimmelman AC, Ying H, Nabioullin R, Ponugoti AH, Wiedemeyer R, Stegh AH, Bradner JE, Ligon KL, Brennan C, Chin L, DePinho RA

  • Science. 2007 Oct 12;318(5848):287-90.

2007-12-12

Fig 1A. Photomicrograph (◊40) of cytokeratin AE1:AE3 immunostain showing the dispersed distribution of metastatic clusters along the subcapsular sinuses of nearly the entire circumference of the lymph node.

Fig 1A. Photomicrograph (◊40) of cytokeratin AE1:AE3 immunostain showing the dispersed distribution of metastatic clusters along the subcapsular sinuses of nearly the entire circumference of the lymph node.
  • Moore KH, Sweeney KJ, Wilson ME, Goldberg JI, Buchanan CL, Tan LK, Liberman L, Turner RR, Lagios MD, Cody Iii HS, Giuliano AE, Silverstein MJ, Van Zee KJ

  • Ann Surg Oncol. 2007 Oct;14(10):2911-7.

2007-12-11

Fig 1. Mechanisms of resistance to targeted cancer therapy.

Fig 1. Mechanisms of resistance to targeted cancer therapy.
  • Charles L. Sawyers

  • Nat Med. 2007 Oct;13(10):1144-5.

2007-12-10

Fig 3. Isodose plot from a treatment plan of a paraspinal tumor.

Fig 3. Isodose plot from a treatment plan of a paraspinal tumor.
  • Mageras GS, Mechalakos J

  • Semin Radiat Oncol. 2007 Oct;17(4):268-77.

2007-12-07

Fig 2C. Reactions catalysed by ribozymes.

Fig 2C. Reactions catalysed by ribozymes.
  • Serganov A, Patel DJ

  • Nat Rev Genet. 2007 Oct;8(10):776-90.

2007-12-06

Fig 6. Granulation tissue showing plump endothelial cells resembling atypical epithelial cells in a fibroblastic stroma.

Fig 6. Granulation tissue showing plump endothelial cells resembling atypical epithelial cells in a fibroblastic stroma.
  • Berney DM, Fisher G, Kattan MW, Oliver RT, M¯ller H, Fearn P, Eastham J, Scardino P, Cuzick J, Reuter VE, Foster CS; Trans-Atlantic prostate group

  • Histopathology. 2007 Oct;51(4):452-7.

2007-12-05

Fig 1. Components of bone marrow.

Fig 1. Components of bone marrow.
  • Hwang S, Panicek DM

  • Skeletal Radiol. 2007 Oct;36(10):913-20.

2007-12-04

Fig 2. An axial slice of a computed tomographic scan through the region of the optic chiasm demonstrating tumor underdose near the optic chiasm.

Fig 2. An axial slice of a computed tomographic scan through the region of the optic chiasm demonstrating tumor underdose near the optic chiasm.
  • Nancy Y. Lee

  • Int J Radiat Oncol Biol Phys. 2007;69(2 Suppl):S43-5.

2007-12-03

Fig 2. The lung shows alveolar edema and fibrin accumulation with early hyaline membrane formation with the pattern of diffuse alveolar damage.

Fig 2. The lung shows alveolar edema and fibrin accumulation with early hyaline membrane formation with the pattern of diffuse alveolar damage.
  • Liu V, White DA, Zakowski MF, Travis W, Kris MG, Ginsberg MS, Miller VA, Azzoli CG

  • Chest. 2007 Sep;132(3):1042-4.

2007-11-30

Fig 4. Cleavage of the Eph-bound ephrins allows for signaling termination and cell separation/repulsion.

Fig 4. Cleavage of the Eph-bound ephrins allows for signaling termination and cell separation/repulsion.
  • Himanen JP, Saha N, Nikolov DB

  • Curr Opin Cell Biol.2007 Oct;19(5):534-42.

2007-11-29

Fig 1. Anatomic retroperitoneal nodal regions.

Fig 1. Anatomic retroperitoneal nodal regions.
  • Carver BS, Shayegan B, Eggener S, Stasi J, Motzer RJ, Bosl GJ, Sheinfeld J

  • J Clin Oncol. 2007 Oct 1;25(28):4365-9.

2007-11-28

Fig 7B. Subcellular localization of PRL1.

Fig 7B. Subcellular localization of PRL1.
  • Sun JP, Luo Y, Yu X, Wang WQ, Zhou B, Liang F, Zhang ZY

  • J Biol Chem. 2007 Sep 28;282(39):29043-51.

2007-11-27

Fig 2. Herpes simplex virus lytic cycle.

Fig 2. Herpes simplex virus lytic cycle.
  • Reinblatt M, Pin RH, Fong Y

  • J Am Coll Surg. 2007 Oct;205(4)Supp1:S69-S75.

2007-11-26

Cover Image - Nov 2007

Cover Image - Nov 2007
  • Avital I, Moreira AL, Klimstra DS, Leversha M, Papadopoulos EB, Brennan M, Downey RJ

  • Stem Cells. 2007 Nov;25(11):2903-9.

2007-11-21

Fig 5. Exo84 genetically interacts with apical and basolateral components.

Fig 5. Exo84 genetically interacts with apical and basolateral components.
  • Blankenship JT, Fuller MT, Zallen JA

  • J Cell Sci. 2007 Sep 1; 17(120):3099-3110.

2007-11-20

Fig 1B. The proposed mechanism of action for the BAR reporter involves Akt-dependent phosphorylation of the Aktpep domain (thick line), which results in its interaction with the FHA2 domain (right).

Fig 1B. The proposed mechanism of action for the BAR reporter involves Akt-dependent phosphorylation of the Aktpep domain (thick line), which results in its interaction with the FHA2 domain (right).
  • Zhang L, Lee KC, Bhojani MS, Khan AP, Shilman A, Holland EC, Ross BD, Rehemtulla A

  • Nat Med. 2007 Sep;13(9):1114-9.

2007-11-19

Fig 2. Schematic model of gA channel formation in lipid bilayers.

Fig 2. Schematic model of gA channel formation in lipid bilayers.
  • Ingolfsson HI, Koeppe RE II, Andersen OS

  • Biochemistry. 2007 Sep 11;46(36):10384-91.

2007-11-16

Fig 1D. Tumor-associated B7-H3 and B7x.

Fig 1D. Tumor-associated B7-H3 and B7x.
  • Zang X, Allison JP

  • Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5271-9.

2007-11-15

Fig 3A. Fluorescent immunohistochemical (IHC) staining for G-CSF protein was performed in the human ES cell lines TC71, SK-ES, and A4573 and compared with a normal human osteoblast cell line.

Fig 3A. Fluorescent immunohistochemical (IHC) staining for G-CSF protein was performed in the human ES cell lines TC71, SK-ES, and A4573 and compared with a normal human osteoblast cell line.
  • Morales-Arias J, Meyers PA, Bolontrade MF, Rodriguez N, Zhou Z, Reddy K, Chou AJ, Koshkina NV, Kleinerman ES

  • Cancer. 2007 Oct 1;110(7):1568-77.

2007-11-14

Fig 1. Experimental design. Adult male rhesus macaques were used to test the effects of busulfan on spermatogenesis and the SSC pool.

Fig 1. Experimental design. Adult male rhesus macaques were used to test the effects of busulfan on spermatogenesis and the SSC pool.
  • Hermann BP, Sukhwani M, Lin CC, Sheng Y, Tomko J, Rodriguez M, Shuttleworth JJ, McFarland D, Hobbs RM, Pandolfi PP, Schatten GP, Orwig KE

  • Stem Cells. 2007 Sep;25(9):2330-8.

2007-11-13

Fig 1. Murray F. Brennan.

Fig 1. Murray F. Brennan.
  • Coit, Daniel

  • J Am Coll Surg. 2007 Oct;205(4 Suppl):S54-8.

2007-11-12

Fig 1. Sequential use of tyrosine kinase inhibitors can select for cells harboring compound kinase domain mutations.

Fig 1. Sequential use of tyrosine kinase inhibitors can select for cells harboring compound kinase domain mutations.
  • Shah NP, Skaggs BJ, Branford S, Hughes TP, Nicoll JM, Paquette RL, Sawyers CL

  • J Clin Invest. 2007 Sep;117(9):2562-9.

2007-11-09

Fig 5. Bioluminescent imaging of NALM-6(GFP-FFLuc) tumor cells after weekly CAR+ T-cell treatment for 4 wks.

Fig 5. Bioluminescent imaging of NALM-6(GFP-FFLuc) tumor cells after weekly CAR+ T-cell treatment for 4 wks.
  • Brentjens RJ, Santos E, Nikhamin Y, Yeh R, Matsushita M, La Perle K, Quint·s-Cardama A, Larson SM, Sadelain M

  • Clin Cancer Res. 2007 Sep 15;13(18):5426-35.

2007-11-08

Fig 5. High-dose IgG protects animals against delayed radiation nephropathy while preserving the therapeutic effect of 225Ac-A33.

Fig 5. High-dose IgG protects animals against delayed radiation nephropathy while preserving the therapeutic effect of 225Ac-A33.
  • Jaggi JS, Carrasquillo JA, Seshan SV, Zanzonico P, Henke E, Nagel A, Schwartz J, Beattie B, Kappel BJ, Chattopadhyay D, Xiao J, Sgouros G, Larson SM, Scheinberg DA

  • J Clin Invest. 2007 Sep;117(9):2422-30.

2007-11-07

Fig 2. Predicted Interactions Verified by IP-MS.

Fig 2. Predicted Interactions Verified by IP-MS.
  • Betel D, Breitkreuz KE, Isserlin R, Dewar-Darch D, Tyers M, Hogue CW

  • PLoS Comput Biol. 2007 Sep 21;3(9):1783-9.

2007-11-06

Fig 4. The Platform-Binding Center for Folded 5´-UTR mRNAs.

Fig 4. The Platform-Binding Center for Folded 5´-UTR mRNAs.
  • Marzi S, Myasnikov AG, Serganov A, Ehresmann C, Romby P, Yusupov M, Klaholz BP

  • Cell. 2007 Sep 21;130(6):1019-31.

2007-11-05

Fig 1B. Immunostaining of FKHR; BPH showing weak cytoplasmic expression.

Fig 1B. Immunostaining of FKHR; BPH showing weak cytoplasmic expression.
  • Li R, Erdamar S, Dai H, Wheeler TM, Frolov A, Scardino PT, Thompson TC, Ayala GE

  • Hum Pathol. 2007 Oct;38(10):1501-7.

2007-11-02

Fig 1. Imaging level shown in vertical histology schematic.

Fig 1. Imaging level shown in vertical histology schematic.
  • Scope A, Benvenuto-Andrade C, Agero AL, Malvehy J, Puig S, Rajadhyaksha M, Busam KJ, Marra DE, Torres A, Propperova I, Langley RG, Marghoob AA, Pellacani G, Seidenari S, Halpern AC, Gonzalez S

  • J Am Acad Dermatol. 2007 Oct;57(4):644-58.

2007-11-01

Fig 1B. Isodose curves of seven-field, dose-painting, intensity-modulated radiotherapy plan for patient with Stage T3N2c supraglottic carcinoma; sagittal view.

Fig 1B. Isodose curves of seven-field, dose-painting, intensity-modulated radiotherapy plan for patient with Stage T3N2c supraglottic carcinoma; sagittal view.
  • Lee NY, O'Meara W, Chan K, Della-Bianca C, Mechalakos JG, Zhung J, Wolden SL, Narayana A, Kraus D, Shah JP, Pfister DG

  • Int J Radiat Oncol Biol Phys. 2007 Oct 1;69(2):459-68.

2007-10-31

Fig 1. Histological features of placental site trophoblastic tumor (hematoxylinñeosin stain).

Fig 1. Histological features of placental site trophoblastic tumor (hematoxylinñeosin stain).
  • Hui P, Wang HL, Chu P, Yang B, Huang J, Baergen RN, Sklar J, Yang XJ, Soslow RA

  • Mod Pathol. 2007 Oct;20(10):1055-60.

2007-10-30

Fig 4. Removal of the left adrenal gland.

Fig 4. Removal of the left adrenal gland.
  • Charlotte Ariyan and

  • Adv Surgery. 2007;41:133-53.

2007-10-29

Fig 5. Active site similarity between Pnkp phosphatase and CTD serine phosphatase.

Fig 5. Active site similarity between Pnkp phosphatase and CTD serine phosphatase.
  • Zhu H, Smith P, Wang LK, Shuman S

  • Virology. 2007 Sep 15;366(1):126-36.

2007-10-26

Fig 1. The Genomic Instability of Cancers Is Important Both in the Evolution of Their Malignant Phenotype and in Providing Potential Targets for Immune-Based Therapeutics.

Fig 1. The Genomic Instability of Cancers Is Important Both in the Evolution of Their Malignant Phenotype and in Providing Potential Targets for Immune-Based Therapeutics.
  • Peggs KS, Segal NH, Allison JP

  • Cancer Cell. 2007 Sep;12(3):192-9.

2007-10-25

Fig 1. Patterns of Genomic Homozygosity and Heterozygosity in ES Cells Derived by Nuclear Transfer and Parthenogenesis from F1 Hybrid Mice.

Fig 1. Patterns of Genomic Homozygosity and Heterozygosity in ES Cells Derived by Nuclear Transfer and Parthenogenesis from F1 Hybrid Mice.
  • Kim K, Ng K, Rugg-Gunn PJ, Shieh JH, Kirak O, Jaenisch R, Wakayama T, Moore MA, Pedersen RA, Daley GQ

  • Cell Stem Cell. 2007 Sep 13; 1(3):346-352.

2007-10-24

Fig 1. Control of the LacZ gene in E. coli.

Fig 1. Control of the LacZ gene in E. coli.
  • Mark Ptashne

  • Current Biology. 2007 Sep 4; 17(17):R740-R741.

2007-10-23

Fig1B. Diffuse and strong positivity for CD99 (O13 antibody).

Fig1B. Diffuse and strong positivity for CD99 (O13 antibody).
  • Wang L, Bhargava R, Zheng T, Wexler L, Collins MH, Roulston D, Ladanyi M

  • J Mol Diagn. 2007 Sep;9(4):498-509.

2007-10-22

Fig 2. IVAMS procedure.

Fig 2. IVAMS procedure.
  • Moreno P, Francos JM, Shaha A, Bosch A, de Lama E, Rafecas A, Jaurrieta E

  • Surgery.2007 Sep;142(3):410-3.

2007-10-19

Fig 3B. Slx8 foci colocalize with replication foci as marked with CFP-Pol30; colocalization is indicated by arrows.

Fig 3B. Slx8 foci colocalize with replication foci as marked with CFP-Pol30; colocalization is indicated by arrows.
  • Burgess RC, Rahman S, Lisby M, Rothstein R, Zhao X

  • Mol Cell Biol. 2007 Sep;27(17):6153-62.

2007-10-18

Fig 2C. Histopathology (◊200) shows intraepidermal collections of atypical lymphocytes or Pautrier's microabscesses and scattered epidermotropic lymphocytes.

Fig 2C. Histopathology (◊200) shows intraepidermal collections of atypical lymphocytes or Pautrier's microabscesses and scattered epidermotropic lymphocytes.
  • Agero AL, Gill M, Ardigo M, Myskowski P, Halpern AC, Gonz·lez S

  • J Am Acad Dermatol. 2007 Sep;57(3):435-41.

2007-10-17

Fig 1. Breast applicator and lead shielding for intraoperative radiotherapy.

Fig 1. Breast applicator and lead shielding for intraoperative radiotherapy.
  • Beal K, McCormick B, Zelefsky MJ, Borgen P, Fey J, Goldberg J, Sacchini V

  • Int J Radiat Oncol Biol Phys. 2007 Sep 1;69(1):19-24.

2007-10-16

Fig 6A. Histologic sections of macrofollicular variant of papillary carcinoma.

Fig 6A. Histologic sections of macrofollicular variant of papillary carcinoma.
  • Chung D, Ghossein RA, Lin O

  • Diagn Cytopathol. 2007 Sep;35(9):560-4.

2007-10-15

Fig 2. Representative photomicrographs of BRCA2-linked tissue specimens before and after laser catapult microdissection.

Fig 2. Representative photomicrographs of BRCA2-linked tissue specimens before and after laser catapult microdissection.
  • King TA, Li W, Brogi E, Yee CJ, Gemignani ML, Olvera N, Levine DA, Norton L, Robson ME, Offit K, Borgen PI, Boyd J

  • Ann Surg Oncol. 2007 Sep;14(9):2510-8.

2007-10-12

Fig 1. A rotational fluoroscopy image of a hepatic artery injection.

Fig 1. A rotational fluoroscopy image of a hepatic artery injection.
  • Coleman J, Nascimento R, Solomon SB

  • Nat Clin Pract Urol. 2007 Sep;4(9):498-504.

2007-10-11

Fig 2. Schematic depiction of transcriptional regulation by post-translational histone modifications.

Fig 2. Schematic depiction of transcriptional regulation by post-translational histone modifications.
  • Wang GG, Allis CD, Chi P

  • Trends Mol Med. 2007 Sep;13(9):363-72.

2007-10-10

Fig 1G. Anti-CD34 staining (brown) of peritubular/interstitial mouse cells, which remain CD34+ (inset, green staining) following in vitro expansion.

Fig 1G. Anti-CD34 staining (brown) of peritubular/interstitial mouse cells, which remain CD34+ (inset, green staining) following in vitro expansion.
  • Seandel M, James D, Shmelkov SV, Falciatori I, Kim J, Chavala S, Scherr DS, Zhang F, Torres R, Gale NW, Yancopoulos GD, Murphy A, Valenzuela DM, Hobbs RM, Pandolfi PP, Rafii S

  • Nature. 2007 Sep 20;449(7160):346-50.

2007-10-09

Fig 4. NUP98-HOXA9 protein is resistant to ubiquitination.

Fig 4. NUP98-HOXA9 protein is resistant to ubiquitination.
  • Moore MA, Chung KY, Plasilova M, Schuringa JJ, Shieh JH, Zhou P, Morrone G

  • Ann N Y Acad Sci. 2007 June;1106:11.

2007-10-08

Fig 1. FC and FCM arrangements during myoblast fusion.

Fig 1. FC and FCM arrangements during myoblast fusion.
  • Beckett K, Baylies MK

  • Dev Biol. 2007 Sep 1;309(1):113-25.

2007-10-05

Fig 1C-D. Examples of clinically significant and insignificant tumor foci in 4 patients; Step-sections from patients 5 and 4, respectively.

Fig 1C-D. Examples of clinically significant and insignificant tumor foci in 4 patients; Step-sections from patients 5 and 4, respectively.
  • Pucar D, Hricak H, Shukla-Dave A, Kuroiwa K, Drobnjak M, Eastham J, Scardino PT, Zelefsky MJ

  • Int J Radiat Oncol Biol Phys. 2007 Sep 1;69(1):62-9.

2007-10-04

Fig 1. Transition structures and activation enthalpies, in italics, for cycloadditions of 1-siloxy-3-methyl-1,3-butadiene with ethylene, butadiene, butenyne, 1-silylbutenyne, acrolein, and -silylethynyl acrolein.

Fig 1. Transition structures and activation enthalpies, in italics, for cycloadditions of 1-siloxy-3-methyl-1,3-butadiene with ethylene, butadiene, butenyne, 1-silylbutenyne, acrolein, and -silylethynyl acrolein.
  • Min SJ, Jones GO, Houk KN, Danishefsky SJ

  • J Am Chem Soc. 2007 Aug 22;129(33):10078-9.

2007-10-03

Fig 6A. Model of the HP1γ chromodomain (displayed as a ribbon beneath a transparent surface) bound to G9a K165me3 peptide.

Fig 6A. Model of the HP1γ chromodomain (displayed as a ribbon beneath a transparent surface) bound to G9a K165me3 peptide.
  • Sampath SC, Marazzi I, Yap KL, Sampath SC, Krutchinsky AN, Mecklenbr‰uker I, Viale A, Rudensky E, Zhou MM, Chait BT, Tarakhovsky A

  • Mol Cell. 2007 Aug 17;27(4):596-608.

2007-10-02

Fig 1A. Representative fluorescence overlay image [pimonidazole (green), Hoechst 33342 (blue), and CA9 (red)] of a section from a macroscopic s.c. xenograft derived from the human colorectal carcinoma cell line HT29.

Fig 1A. Representative fluorescence overlay image [pimonidazole (green), Hoechst 33342 (blue), and CA9 (red)] of a section from a macroscopic s.c. xenograft derived from the human colorectal carcinoma cell line HT29.
  • Li XF, Carlin S, Urano M, Russell J, Ling CC, O'Donoghue JA

  • Cancer Res. 2007 Aug 15;67(16):7646-53.

2007-10-01

Fig 1. Cancer immunoediting: from immunosurveillance to immunoevasion.

Fig 1. Cancer immunoediting: from immunosurveillance to immunoevasion.
  • Rescigno M, Avogadri F, Curigliano G

  • Biochim Biophys Acta 2007 Sep;1776(1):108-23.